Clinical Trial Detail

NCT ID NCT03012100
Title Multi-epitope Folate Receptor Alpha Peptide Vaccine, GM-CSF, and Cyclophosphamide in Treating Patients With Triple Negative Breast Cancer
Recruitment Recruiting
Gender female
Phase Phase II
Variant Requirements No
Sponsors Academic and Community Cancer Research United
Indications

triple-receptor negative breast cancer

Therapies

Cyclophosphamide + Sargramostim

Cyclophosphamide + FR alpha peptide vaccine + Sargramostim

Age Groups: adult senior

No variant requirements are available.